Actavis chairman joins Zoetis board under deal with activist investor Ackman

Pfizer ($PFE) spinoff Zoetis ($ZTS), the animal health company, added a second director to its board under a deal it reached earlier this year with activist investor Bill Ackman and his firm Pershing Square Capital Management. The new board member is Actavis ($ACT) Chairman Paul Bisaro, who helped engineer a takeover of Allergan--a deal that delivered billions of payoffs for Ackman, one of the company's top shareholders. Ackman had teamed up with Valeant Pharmaceuticals ($VRX) in a hostile bid for Allergan before Actavis swooped in with a higher offer. Report

Suggested Articles

Researchers scoured the database where pharma companies disclose payments made to physicians and discovered a troubling trend.

Just a few months after playing a pivotal role in Sanofi’s Bioverativ buy, Alex Denner has set his sights on Ironwood.

Clovis' new approval will boost Rubraca in recurrent ovarian cancer, but because of its competitors' head start, the race will be tough.